Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham P Collins

Showing results (101-110 of 164) with videos related to

Pageof 17
Sort By:
Frontiers in Pharmacology|October 5, 2020
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity StudyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
British Journal of Haematology|March 10, 2016
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphomaToby A Eyre, Kim M Linton, Phillipa Rohman, et al.
Blood|February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaAriela Noy, Sven de Vos, Catherine Thieblemont, et al.
Journal of Comparative Effectiveness Research|May 1, 2019
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence studyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Lancet (London, England)|July 2, 2023
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testingRatna Wijaya, Marina Johnson, Nicola Campbell, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
British Journal of Haematology|April 26, 2019
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOPToby A Eyre, Nicolas Martinez-Calle, Catherine Hildyard, et al.
Cancer|October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancerToby A Eyre, Graham P Collins, Avinash Gupta, et al.
British Journal of Haematology|June 22, 2019
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicityToby A Eyre, Amy A Kirkwood, Julia Wolf, et al.
Pageof 17

Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
Frontiers in Pharmacology|October 5, 2020
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity StudyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
British Journal of Haematology|March 10, 2016
Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphomaToby A Eyre, Kim M Linton, Phillipa Rohman, et al.
Blood|February 8, 2017
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaAriela Noy, Sven de Vos, Catherine Thieblemont, et al.
Journal of Comparative Effectiveness Research|May 1, 2019
Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence studyPushpendra Goswami, Esther N Oliva, Tatyana Ionova, et al.
Lancet (London, England)|July 2, 2023
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testingRatna Wijaya, Marina Johnson, Nicola Campbell, et al.
The Lancet. Haematology|May 28, 2021
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion studyMehdi Hamadani, Graham P Collins, Paolo F Caimi, et al.
British Journal of Haematology|September 14, 2020
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)Adam Gibb, Sarah J Pirrie, Kim Linton, et al.
British Journal of Haematology|April 26, 2019
Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOPToby A Eyre, Nicolas Martinez-Calle, Catherine Hildyard, et al.
Cancer|October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancerToby A Eyre, Graham P Collins, Avinash Gupta, et al.
British Journal of Haematology|June 22, 2019
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicityToby A Eyre, Amy A Kirkwood, Julia Wolf, et al.
Pageof 17